ACE polymorphism and response to electroconvulsive therapy in major depression

Neuroscience Letters

Volumn 458, Issue 3, 2009, Pages 122-125

  Stewart, Juhani Akseli ^a   Kampman, Olli ^a,c   Huuhka, Martti ^a,b   Anttila, Sami ^a,b   Huuhka, Kaija ^a,b   Lehtimäki, Terho ^a,b   Leinonen, Esa ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c SEINÄJOKI CENTRAL HOSPITAL   (Finland)

Author keywords

ACE gene polymorphism; Antidepressive agents; Depression; Electroconvulsive therapy; Pharmacogenetics

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; ELECTROCONVULSIVE THERAPY; FEMALE; GENOTYPE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL;

ADULT; AGE OF ONSET; AGED; DEPRESSIVE DISORDER, MAJOR; DNA; DNA PRIMERS; ELECTROCONVULSIVE THERAPY; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PEPTIDYL-DIPEPTIDASE A; PERSONALITY INVENTORY; POLYMORPHISM, GENETIC; REFERENCE VALUES; TREATMENT OUTCOME;

EID: 65549092878     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.04.057     Document Type: Article

References (39)

1. Anttila S., Huuhka K., Huuhka M., Rontu R., Mattila K., Leinonen E., and Lehtimäki T. Interaction between TPH1 and GNB3 genotypes and electroconvulsive therapy in major depression. J. Neural Transm. 114 4 (2007) 461-468
2. Anttila S., Huuhka K., Huuhka M., Illi A., Rontu R., Leinonen E., and Lehtimäki T. Catechol-O-methyltransferase (COMT) polymorphisms predict treatment response in electroconvulsive therapy. Pharmacogenomics J. 8 (2008) 113-116
3. Arinami T., Liming L., Mitsushio H., Itokawa M., Hamaguchi H., and Toru M. An Insertion/deletion polymorphism in the angiotensin converting enzyme gene is associated with both brain substance P contents and affective disorders. Biol. Psychiatry 40 (1996) 1122-1127
4. Ariza M., del Matarin M., Junqué C., Mataró M., Immaculada C., Moral P., Poca M., Garnacho A., and Sahuquillo J. Influence of angiotensin-converting enzyme polymorphism on neuropsychological subacute performance in moderate and severe traumatic brain injury. J. Neuropsychiatry Clin. Neurosci. 18 (2006) 39-44
5. Arregui A., Mackay A.V., Spokes E.G., and Iversen L.L. Reduced activity of angiotensin-converting enzyme in basal ganglia in early onset schizophrenia. Psychol. Med. 10 2 (1980) 307-313
6. Baghai T., Schule C., Zwanzger P., Minov C., Zill P., Ella R., Eser D., Oezer S., Bondy B., and Rupprecht R. Hypothalamic-pituitary-adrenocortical axis dysregulation in patients with major depression is influenced by the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene. Neurosci. Lett. 358 (2002) 299-303
7. Baghai C., Schüle P., Zwanzger C., Minov M., Schwarz S., de Jonge R., Ruprecht B., and Bondy. Possible influence of the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene on therapeutic outcome in affective disorders. Mol. Psychiatry 6 3 (2001) 258-259
8. Baghai T.C., Schule C., Zill P., Deiml T., Eser D., Zwanzger P., Ella R., Rupprecht R., and Bondy B. The angiotensin I converting enzyme insertion/deletion polymorphism influences therapeutic outcome in major depressed women, but not in men. Neurosci. Lett. 363 (2004) 38-42
9. Baghai T.C., Binder E.B., Schule C., Salyakina D., Eser D., Lucae S., Zwanzger P., and Haberger C. Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism. Mol. Psychiatry 11 (2006) 1003-1015
10. Beck A.T., Ward C.H., Mendelson M., Mock J., and Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry 4 (1961) 53-63
11. Comings D., and MacMurray J. Molecular heterosis, a review. Mol. Genet. Metab. 71 (2000) 19-31
12. Dailly E., Chenu F., Renard C.E., and Bourin M. Dopamine, depression and antidepressants. Fundam. Clin. Pharmacol. 18 6 (2004) 601-607
13. Diagnostic and Statistical Manual of Mental Disorders, 4th revised edition, American Psychiatric Association, Washington, DC, 1994.
14. Ebert D., and Lammers C.H. The central dopaminergic system and depression. Nervenartz 68 7 (1997) 545-555
15. Folstein M.F., Folstein S.E., and McHugh P.R. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12 (1975) 189-198
16. Furlong R., Keramatipour M., Ho L., Rubinsztein J., Michael A., Walsh C., Paykel E., and Rubinsztein D. No association of an insertion/deletion polymorphism in the angiotensin I converting enzyme gene with bipolar or unipolar affective disorders. Am. J. Med. Genet. (Neuropsychiatr. Genet.) 96 (2000) 733-735
17. Hong C.-J., Wang Y.-C., and Tsai S.-J. Association study of angiotensin I-converting enzyme polymorphism and symptomatology and antidepressant response in major depressive disorders. J. Neural Transm. 109 (2002) 1209-1214
18. Huang X.-H., Salomäki A., Malin R., Koivula T., Jokela H., and Lehtimäki T. Rapid identification of angiotensin-converting enzyme genotypes by capillary electrophoresis. Clin. Chem. 43 (1997) 2195-2196
19. Huuhka M. Academic Dissertation: Electroconvulsive Therapy in Major Depression-A Clinical and Genetic Approach (2005), Acta Universitatis Tamperensis 1102, Tampere University Press, Tampere
20. Huuhka M., Anttila S., Leinonen E., Huuhka K., Rontu R., Mattila K., Huhtala H., and Lehtimäki T. The apolipoprotein E polymorphism is not associated with response to electroconvulsive therapy in major depressive disorder. J. ECT 21 1 (2005) 7-11
21. Illi A., Kampman O., Anttila S., Roivas M., Mattila K., Lehtomäki T., and Leinonen E. Interaction between angiotensin-converting enzyme and catechol-O-methyltransferase genotypes in schizophrenics with poor response to conventional neuroleptics. Eur. Neuropsychopharmacol. 13 (2003) 147-151
22. Jenkins T.A., Wong J.Y., Howells D.W., Mendelsohn F.A., and Chai S.Y. Effect of chronic angiotensin-converting enzyme inhibition on striatal dopamine content in the MPTP-treated mouse. J. Neurochem. 73 1 (1999) 214-219
23. Judd L.L. Mood disorders in the general population represent an important and worldwide public health problem. Int. Clin. Psychopharmacol. 10 Suppl. (1995) 5-10
24. Lindeman S., Hämäläinen J., Isometsä H., Kaprio J., Poikolainen K., Heikkinen M., and Aro H. The 12-month prevalence and risk factors for major depressive episode in Finland: representative sample of 5993 adults. Acta Psychiatr. Scand. 102 (2000) 178-184
25. Markianos M., Hatzimanolis J., and Lykouras L. Serotonergic and dopaminergic neuroendocrine responses of male depressive patients before and after a therapeutic ETC course. Eur. Arch. Psychiatry Clin. Neurosci. 252 4 (2002) 172-176
26. Mayur P.M., Gangadhar B.N., Subbakrishna D.K., and Janakiramaiah N. Discontinuation of antidepressant drugs during electroconvulsive therapy: a controlled study. J. Affect. Disord. 58 1 (2000) 37-41
27. McGarvey K.A., Zis A.P., Brown E.E., Nomikos G.G., and Fibiger H.C. ECS-induced dopamine release: effects of electrode placement, anticonvulsant treatment, and stimulus intensity. Biol. Psychiatry 34 3 (1993) 152-157
28. Montgomery S.A., and Åsberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134 (1979) 382-389
29. Nutt D.J. The role of dopamine and norepinephrine in depression and antidepressant treatment. J. Clin. Psychiatry 67 6 (2006) 3-8
30. Olsson M., Annerbrink K., Westberg L., Melke J., Baghaei F., Rosmond R., Holm G., Andersch S., Allgulander C., and Eriksson E. Angiotensin-related genes in patients with panic disorder. Am. J. Med. Genet. Part B (Neuropsychiatr. Genet.) 127B (2004) 81-84
31. Owen R.T. Neuropharmacological supersensitivity-clinical and experimental correlates and methodological considerations. Clin. Pharmacol. 2 2 (1980) 89-95
32. Pauls J., Bandelow B., Rüther E., and Kornhuber J. Polymorphism of the gene of angiotensin converting enzyme-lack of association with mood disorder. J. Neural Transm. 107 (2000) 1361-1366
33. Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., and Soubrier F. An insertion/deletion polymorphism in the angiotensin i-converting enzyme gene accounting for half the variance of serum enzyme levels. Am. Soc. Clin. Invest. 86 (1990) 1343-1346
34. Rodriguez-Pallares J., Rey P., Parga J.A., Munoz A., Guerra M.J., and Labandeira-Garcia J.L. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol. Dis. 31 1 (2008) 58-73
35. Sackeim H.A., Haskett R.F., Mulsant B.H., Thase M.E., Mann J.J., Pettinati H.M., Greenberg R.M., Crowe R.R., Cooper T.B., and Prudic J. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA 285 10 (2001) 1299-1307
36. Segman R., Shapira Y., Modai I., Hamdan A., Zislin J., Heresco-Lewy U., Kanyas K., Hirschmann S., Karni O., Finkel B., Schlafman M., Lerner A., Shapira B., Macciardi F., and Lerer B. Angiotensin converting enzyme gene insertion/deletion polymorphism: case-control association studies in schizophrenia, major affective disorder, and tardive dyskinesia and a family-based association study in schizophrenia. Am. J. Med. Genet. (Neuropsychiatr. Genet.) 114 (2002) 310-314
37. Serretti A., and Artioli P. From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes. Psychopharmacology 174 (2004) 490-503
38. Swartz C.M., and Abrams R. ECT Instruction Manual. 6th edition (1996), Somatic Inc., Lake Bluff, IL
39. Wahlbeck K., Rimon R., and Fyhrquist F. Elevated angiotensin-converting enzyme (kininase II) in the cerebrospinal fluid of neuroleptic-treated schizophrenic patients. Schizophr. Res. 9 1 (1993) 77-82